Your browser doesn't support javascript.
loading
Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
Díaz-Menéndez, M; de la Calle-Prieto, F; Montejano, R; Arsuaga, M; Jiménez-González, M; Pérez-Blanco, V; Marcelo, C; Vásquez-Manau, J; Lázaro, F; Arribas, J R.
Afiliação
  • Díaz-Menéndez M; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain. Electronic address: marta.diaz@salud.madrid.org.
  • de la Calle-Prieto F; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Montejano R; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Arsuaga M; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Jiménez-González M; HIV/AIDS and Infectious Diseases Group. Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Pérez-Blanco V; Preventive Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Marcelo C; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Vásquez-Manau J; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Lázaro F; Microbiology Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
  • Arribas JR; Infectious Disease Unit, Internal Medicine Department, Hospital Universitario La Paz. IdiPAZ, Madrid, Spain.
Vaccine ; 40(32): 4307-4311, 2022 07 30.
Article em En | MEDLINE | ID: mdl-35701328
ABSTRACT
We described clinical characteristics and outcome of 160 patients over 65 years (01 September to 31 August 2021) who had a first positive SARS-CoV-2 PCR- test more than 14 days after full vaccination and were hospitalized with COVID-19. Median age of included patients was 84 years, 61.2% were over 80 years; 50.6% were male and most (82.5%) has at least one comorbidity. Up to 84% received specific treatment against COVID-19, including 76.9% low-flow oxygen therapy. We found that overall mortality was 25.6% and 30.6% in those older than 80 years. A higher mortality was significantly associated with older age and treatment with tocilizumab. Our data showed that although COVID-19 vaccines continue protecting elderly patients against hospitalization and death and might improve the prognosis after hospitalization in patients with breakthrough infections, mortality in this population -especially in those older than 80 years- remains very high.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Vaccine Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Vaccine Ano de publicação: 2022 Tipo de documento: Article